Skip to main content
. 2018 Feb 5;131(14):1532–1544. doi: 10.1182/blood-2017-05-783845

Figure 5.

Figure 5.

Healthy E2f1−/−SPCs cells retain functionality. (A) E2f1−/− or WT BM LSK cells transplanted into lethally irradiated CD45.1+ WT recipient mice (n = 5) for long-term reconstitution (i). Sixteen weeks posttransplantation, CD45.2+ LSK WT or E2f1−/− cells purified from harvested BM and transplanted into lethally irradiated CD45.1+ WT secondary recipient mice (N = 4/5) (ii). The engraftment ability of E2f1+/+ WT (black) and E2f1−/− (gray) LSK cells was assessed by the percentage of CD45.2+/CD45.1− cells in PB at weeks 4, 8, 12, and 16 post primary and secondary transplantation. (Bi) Schematic representation of experimental design. E2f1−/− (CD45.2+) and E2f1+/+ WT BM cells (CD45.1+) were transplanted in ratios of 9:1, 1:1, and 1:9 into lethally irradiated (7Gy) CD45.1+ WT recipient mice (N = 5) for long-term reconstitution. (ii) Percentages of CD45.2+ E2f1−/− donor vs recipient cells (CD45.1+) at weeks 4, 8, 12, and 16 posttransplant. NS, not significant with P > .05.